KEAP1 and malignant peripheral nerve sheath tumor: This study evaluates the clinical activity of telaglenastat (CB-839), a glutaminase inhibitor, in solid tumors or malignant peripheral nerve sheath tumors with NF1, KEAP1/NRF2, or LKB1 mutations